中文
Earlier issues
Announcement
More
Progress in Chemistry 2013, Vol. 25 Issue (09): 1450-1453 DOI: 10.7536/PC130408 Previous Articles   Next Articles

Aspirin for the Prevention of Colorectal Cancer

Andrew T. Chan*   

  1. Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
  • Received: Online: Published:
  • Contact: Andrew T. Chan E-mail:achan@partners.org
Richhtml ( 2 ) PDF ( 929 ) Cited
Export

EndNote

Ris

BibTeX

Consistent experimental, epidemiologic, and recent randomized controlled trial evidence demonstrates that aspirin lowers the risk of colorectal cancer (CRC). Prior expert bodies have recommended against the routine use of aspirin to prevent CRC in individuals at average risk, particularly in view of potential adverse consequences, including gastrointestinal bleeding. However, such recommendations preceded more recent high quality evidence of the benefit of aspirin for the prevention of not only colorectal cancer, but other cancers as well. This review summarizes this compelling body of evidence supporting the chemopreventive efficacy of aspirin. A broad anti-cancer effect of aspirin coupled with its potential role in the prevention of cardiovascular disease may tip the balance in favor of chronic aspirin use for many patients.

Key words: aspirin, colorectal cancer, randomized controlled trials, nonaspirin nonsteroidal antiinflammatory drugs, chemoprevention

CLC Number: 

[1] Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Int. J. Cancer, 2011, 127: 2893—917
[2] Shapiro J A, Seeff L C, Thompson T D, Nadel M R, Klabunde C N, Vernon S W. Colorectal Cancer Test Use from the 2005 National Health Interview Survey. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008, 17: 1623—1630
[3] Chan A T, Giovannucci E L. Gastroenterology, 2010, 138: 2029—2043 e10
[4] Cole B F, Logan R F, Halabi S, Benamouzig R, Sandler R S, Grainge M J, Chaussade S, Baron J A. J. Natl. Cancer Inst., 2009, 101: 256—266
[5] Routine Aspirin or Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U. S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 2007, 146: 361—364
[6] Rothwell P M, Wilson M, Elwin C E, Norrving B, Algra A, Warlow C P, Meade T W. The Lancet, 2010, 376: 1741—1750
[7] Rothwell P M, Fowkes F G, Belch J F, Ogawa H, Warlow C P, Meade T W. The Lancet, 2011, 377: 31—41
[8] Cook N R, Lee I M, Gaziano J M, Gordon D, Ridker P M, Manson J E, Hennekens C H, Buring J E. JAMA, 2005, 294: 47—55
[9] Sturmer T, Glynn R J, Lee I M, Manson J E, Buring J E, Hennekens C H. Ann. Intern. Med., 1998, 128: 713—720
[10] Burn J, Bishop D T, Mecklin J P, Macrae F, Moslein G, Olschwang S, Bisgaard M L, Ramesar R, Eccles D, Maher E R, Bertario L, Jarvinen H J, Lindblom A, Evans D G, Lubinski J, Morrison P J, Ho J W, Vasen H F, Side L, Thomas H J, Scott R J, Dunlop M, Barker G, Elliott F, Jass J R, Fodde R, Lynch H T, Mathers J C. N. Engl. J. Med., 2008, 359: 2567—2578
[11] Burn J, Gerdes A, Macrae F, Mecklin J, Moslein G, Olschwang S, Eccles D, Evans G, Bertario L, Bisgaard M, Dunlop M, Ho J W, Hodgson S, Lindblom A, Lubinski J, Morrison P J, Murday V, Ramesar R, Side L, Scott R J, Thomas J W, Vasen H F, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Mathers J C, Bishop D T. The Lancet, 2011, 378: 2081—2087
[12] Sostres C, Lanas A. Nature Reviews Gastroenterology & Hepatology, 2011, 8: 385—394
[13] Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133:199S—233S
[14] Final Report on the Aspirin Component of the Ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med., 1989, 321: 129—135
[15] Ridker P M, Cook N R, Lee I M, Gordon D, Gaziano J M, Manson J E, Hennekens C H, Buring J E. N. Engl. J. Med., 2005, 352: 1293—1304
[16] Chan A T, Ogino S, Fuchs C S. JAMA, 2009, 302: 649—658
[17] Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian Z R, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt J A, Giovannucci E, Fuchs C S, Chan A T, Ogino S. N. Engl. J. Med., 2012, 367: 1596—1606
[18] Aspirin for the Prevention of Cardiovascular Disease: U. S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med., 2009, 150: 396—404
[1] Michael B. Sporn, Karen T. Liby. A Mini-Review of Chemoprevention of Cancer——Past, Present, and Future [J]. Progress in Chemistry, 2013, 25(09): 1421-1428.
[2] Patricia A. Egner, Jin-Bing Wang, Yuan-Rong Zhu, Lisa P. Jacobson, Derek Ng, Alvaro Muñoz, Jed W. Fahey, Jian-Guo Chen, Tao-Yang Chen, Geng-Sun Qian, John D. Groopman, Thomas W. Kensler*. Prevention of Liver Cancer in Qidong, China：Lessons from Aflatoxin Biomarker Studies [J]. Progress in Chemistry, 2013, 25(09): 1454-1461.
[3] Li Junyao. Nutritional Intervention of Cancer [J]. Progress in Chemistry, 2013, 25(09): 1462-1479.
[4] Gary D. Stoner. Whole Food Approach to Cancer Prevention：Berries as an Example [J]. Progress in Chemistry, 2013, 25(09): 1480-1491.
[5] Zheng-Yuan Su, Limin Shu, Jong Hun Lee, Franciso Fuentes, Hu Wang, Tien-Yuan Wu, Siwang Yu, Ah-Ng Tony Kong. Perspective on Nrf2, Epigenomics and Cancer Stem Cells in Cancer Chemoprevention Using Dietary Phytochemicals and Traditional Chinese Medicines [J]. Progress in Chemistry, 2013, 25(09): 1526-1543.
[6] Wang Xiu Jun*, Li Xin, Tang Xiuwen. The Role of Nrf2 in Carcinogenesis [J]. Progress in Chemistry, 2013, 25(09): 1544-1552.
[7] Song Gao, Sumit Basu, Guangyi Yang, Arijita Deb, Ming Hu. Oral Bioavailability Challenges of Natural Products Used in Cancer Chemoprevention [J]. Progress in Chemistry, 2013, 25(09): 1553-1574.
[8] Tao Niu, Ming Hu. Microbiota Structures, Human Health and Cancer Chemoprevention [J]. Progress in Chemistry, 2013, 25(09): 1601-1612.